Role of nanoparticle-mediated immunogenic cell death in cancer immunotherapy.
Immunogenic cell death
Immunotherapy
Multimodal cancer therapy
Nanoformulation
Nanoparticle
Journal
Asian journal of pharmaceutical sciences
ISSN: 2221-285X
Titre abrégé: Asian J Pharm Sci
Pays: Netherlands
ID NLM: 101535338
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
30
03
2020
revised:
15
05
2020
accepted:
31
05
2020
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
ppublish
Résumé
Cancer immunotherapy, which suppresses cancer progression by activating the anti-cancer immunity of patients, shows utility in treating multiple types of cancers. Immunogenic cell death (ICD) induced by most clinical treatment modalities plays a critical role in promoting cancer immunotherapy by releasing tumor-associated antigens and neoantigens and exposing "danger signals" to stimulate immune cells. This comment article presents the different roles of nanoparticles in various treatment modalities of cancers, including chemotherapy, radiotherapy, photodynamic and photothermal therapies, and therapy with radiated tumor cell-released nanoparticles, which often activate anti-cancer immunological effects by inducing ICD of cancer cells, and highlights the challenges and opportunities of ICD-related cancer immunotherapy in the clinic.
Identifiants
pubmed: 33995609
doi: 10.1016/j.ajps.2020.05.004
pii: S1818-0876(20)30384-6
pmc: PMC8105413
doi:
Types de publication
Journal Article
Langues
eng
Pagination
129-132Informations de copyright
© 2020 Shenyang Pharmaceutical University. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.
Références
Adv Funct Mater. 2020 Mar 17;30(12):
pubmed: 33071706
Adv Sci (Weinh). 2020 Feb 20;7(7):1902576
pubmed: 32274298
Sci Adv. 2020 Mar 25;6(13):eaay9789
pubmed: 32232155
Adv Mater. 2019 Mar;31(10):e1802228
pubmed: 30663118
J Am Chem Soc. 2018 May 2;140(17):5670-5673
pubmed: 29665677
Adv Sci (Weinh). 2019 Jan 30;6(6):1801868
pubmed: 30937266
Oncoimmunology. 2017 Oct 4;6(12):e1386829
pubmed: 29209573
ACS Nano. 2019 Nov 26;13(11):12638-12652
pubmed: 31625721
ACS Nano. 2020 Jan 28;14(1):620-631
pubmed: 31877023
Adv Mater. 2019 Apr;31(14):e1805888
pubmed: 30762908
Nat Nanotechnol. 2017 Sep;12(9):877-882
pubmed: 28650437
Nat Rev Cancer. 2012 Dec;12(12):860-75
pubmed: 23151605
Chem Soc Rev. 2019 Nov 11;48(22):5506-5526
pubmed: 31589233
Adv Sci (Weinh). 2019 Jun 21;6(17):1900101
pubmed: 31508270
Front Immunol. 2015 Aug 07;6:402
pubmed: 26300886